Hottest Stories on Wall Street: Halozyme Therapeutics (NASDAQ:HALO), Penn West Petroleum (NYSE:PWE), uniQure N.V. (NASDAQ:QURE), Novavax (NASDAQ:NVAX)

On 18 March, SINA Corporation (NASDAQ:SINA) shares moved down -0.17% and was closed at $47.78. SINA EPS growth in last 5 year was -18.70%. SINA Corporation (NASDAQ:SINA) year to date (YTD) performance is -3.28%.

SINA Corporation (NASDAQ:SINA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, Market Beat Ratings reports.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares advanced 3.58% in last trading session and ended the day at $8.39. HALO Gross Margin is 78.40% and its has a return on assets of -19.20%. Halozyme Therapeutics, Inc. (NASDAQ:HALO) quarterly performance is -48.97%.

Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present preclinical data from five studies at the American Association of Cancer Research (AACR) annual conference next month, including results from its ongoing research of lead investigational agent, PEGPH20, and two novel pipeline assets engineered for increased action in the tumor microenvironment. The AACR annual conference will take place April 17-20 in New Orleans.

Penn West Petroleum Ltd. (NYSE:PWE) caters to the Basic Materials space. Its weekly performance is -12.02%. On the last day of trading company shares ended up at $0.92. Penn West Petroleum Ltd. (NYSE:PWE) distance from 50-day simple moving average (SMA50) is 8.80%.

On 10 March, Penn West Petroleum Ltd. (NYSE:PWE) announces that it has filed with Canadian securities regulatory authorities its audited Consolidated Financial Statements for the year ended December 31, 2015 and related Management’s Discussion and Analysis. Penn West has also filed its Annual Information Form for the year ended December 31, 2015, which includes the disclosure and reports relating to reserves data and other oil and gas information required pursuant to National Instrument 51-101. Penn West’s Annual Report on Form 40-F for the year ended December 31, 2015 will be filed with the U.S. Securities and Exchange Commission pursuant to its rules and regulations.

uniQure N.V. (NASDAQ:QURE) shares increased 6.28% in last trading session and ended the day at $11.84. QURE Gross Margin is 93.90% and its has a return on assets of -40.90%. uniQure N.V. (NASDAQ:QURE) quarterly performance is -31.68%.

On 14 March, uniQure N.V. (NASDAQ:QURE) announced that the Company has treated the first patient in the second cohort of its ongoing AMT-060-01 Phase I/II trial in hemophilia B patients. The primary objective of the second cohort is to assess the safety of the systemic administration of a higher dose of uniQure’s AMT-060 gene therapy in hemophilia B patients that present with a severe or moderately-severe disease phenotype. Secondary objectives of the trial include evaluation of Factor IX (FIX) activity levels as well as evaluation of annualized bleeding rates and recombinant FIX usage.

Novavax, Inc. (NASDAQ:NVAX) caters to the Healthcare space. Its weekly performance is 3.89%. On the last day of trading company shares ended up at $5.07. Novavax, Inc. (NASDAQ:NVAX) distance from 50-day simple moving average (SMA50) is 2.36%.

On 17 March, Novavax, Inc. (NASDAQ:NVAX) announced that Dr. Gregory M. Glenn has been named President, Research & Development. Dr. Glenn joined Novavax as its Chief Scientific Officer in July 2010. Previously, Dr. Glenn was Chief Scientific Officer and founder of IOMAI Corporation, acquired by Intercell in 2008.